By: IPP Bureau
Last updated : January 22, 2025 11:22 am
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. Glenmark's Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, ANDA 087955.
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."